Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Marie Skłodowska-Curie Action · Running

ModProtease Design of ModProtease through High-Throughput Screening Technologies for Therapeutic Applications

Coordinator
The Chancellor Masters and Scholars of the University of Cambridge, United Kingdom
Runs
1 June 2026 to 31 May 2028
Status
Running
EU funding
€260k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101208415

What the project is doing

In the project's own words, from its summary on CORDIS.

The integration of ModProtease with antibody-based systems represents a promising strategy for targeted cancer therapy, particularly in addressing the challenges posed by KRAS mutations. These mutations are notoriously difficult to target directly with antibodies due to their involvement in intracellular signalling pathways and the development of resistance mechanisms. Strategies to overcome these limitations could include the development of protease-antibody conjugates and these conjugates might be directed to cleave specific substrates within tumour microenvironment, thereby enhancing the therapeutic effect of the antibody while minimizing off-target effects.

However, engineered proteases remain underrepresented amongst protein-based biopharmaceuticals. This situation is due to fundamental challenges that exist in redirecting the substrate specificity of proteases. We propose a high-throughput screening platform that employs monoclonal hydrogel microbeads containing target substrates with FRET-based detection systems allowing for the precise identification of protease activity.

This enables the rapid evaluation of various ModProtease variants and their effectiveness when conjugated to antibodies. The interplay of the SpyCatcher-SpyTag system enables the efficient and specific conjugation of ModProteases to antibodies, facilitating the creation of potent antibody-protease. Following high-throughput screening using fluorescence-activated bead sorting (FABS), the platform facilitates the recovery and analysis of protease genotypes from the microbeads.

The group of Prof. Hollfelder (University of Cambridge) has substantial expertise in high-throughput methods and regarding the biology of proteases and protein binders. These conditions make the Host laboratory ideal for this project and will provide critical insights and technical support. This project will also collaborate with AstraZeneca, and targeted proteolysis against cancer cells will be assessed.

Topics

Who is involved

OrganisationCityCountryRole
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI